XENE
Xenon Pharmaceuticals Inc. NASDAQ Listed Nov 5, 2014$56.00
After hrs
$56.44
+0.00%
Mkt Cap $4.4B
52w Low $28.19
77.8% of range
52w High $63.95
50d MA $54.65
200d MA $43.65
P/E (TTM)
-12.9x
EV/EBITDA
-9.8x
P/B
7.7x
Debt/Equity
0.0x
ROE
-59.5%
P/FCF
-12.7x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$54.65
200d MA
$43.65
Avg Volume
1.4M
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
3650 Gilmore Way · Burnaby, BC V5G 4W8 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -1.20 | -1.31 | -9.2% | 44.92 | +1.1% | -3.8% | -5.3% | -2.5% | -4.2% | -6.4% | — |
| Nov 3, 2025 | AMC | -1.16 | -1.15 | +0.9% | 41.12 | -3.4% | -4.9% | -6.0% | -6.9% | -7.0% | -6.6% | — |
| Aug 11, 2025 | AMC | -1.03 | -1.07 | -3.9% | 34.11 | +5.5% | +5.5% | +10.4% | +11.3% | +12.1% | +10.9% | — |
| May 12, 2025 | AMC | -0.94 | -0.83 | +11.7% | 35.85 | -8.5% | -17.4% | -17.0% | -17.5% | -15.5% | -13.7% | — |
| Feb 27, 2025 | AMC | -0.89 | -0.84 | +5.6% | 38.31 | -3.4% | -3.4% | -6.6% | -6.0% | -3.0% | -2.7% | — |
| Nov 12, 2024 | AMC | -0.82 | -0.81 | +0.7% | 43.39 | -0.7% | -3.3% | -3.8% | -8.2% | -11.7% | -10.5% | — |
| Aug 8, 2024 | AMC | -0.72 | -0.75 | -4.2% | 41.01 | -10.0% | -3.2% | -5.3% | -5.4% | -5.6% | -6.7% | — |
| May 9, 2024 | AMC | -0.69 | -0.62 | +10.1% | 42.49 | -4.1% | -4.6% | -4.7% | -4.5% | -4.8% | -5.1% | — |
| Feb 29, 2024 | AMC | -0.76 | -0.64 | +15.8% | 47.20 | +5.3% | -0.8% | -2.6% | -2.5% | -2.6% | -2.2% | — |
| Nov 8, 2023 | AMC | -0.75 | -0.73 | +2.7% | 32.15 | +4.0% | -6.7% | -10.3% | -7.6% | -7.5% | -9.3% | — |
| Aug 9, 2023 | AMC | -0.69 | -0.72 | -4.3% | 35.45 | +2.2% | +8.3% | +6.3% | +5.9% | +5.4% | +2.9% | — |
| May 9, 2023 | AMC | -0.62 | -0.63 | -1.6% | 43.54 | -4.0% | -5.5% | -5.9% | -7.8% | -4.1% | -5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 | Wedbush | Maintains | Outperform → Outperform | — | $55.23 | $55.00 | -0.4% | -1.0% | -0.1% | -0.3% | -0.1% | -0.5% |
| Mar 10 | Deutsche Bank | Maintains | Buy → Buy | — | $62.76 | $63.26 | +0.8% | -3.4% | -5.9% | -7.7% | -12.0% | -12.9% |
| Mar 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $62.76 | $63.26 | +0.8% | -3.4% | -5.9% | -7.7% | -12.0% | -12.9% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.76 | $63.26 | +0.8% | -3.4% | -5.9% | -7.7% | -12.0% | -12.9% |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $62.76 | $63.26 | +0.8% | -3.4% | -5.9% | -7.7% | -12.0% | -12.9% |
| Mar 9 | Baird | Maintains | Outperform → Outperform | — | $41.94 | $60.56 | +44.4% | +49.6% | +44.5% | +40.8% | +38.1% | +31.7% |
| Mar 9 | Needham | Maintains | Buy → Buy | — | $41.94 | $60.56 | +44.4% | +49.6% | +44.5% | +40.8% | +38.1% | +31.7% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $44.92 | $45.40 | +1.1% | -3.8% | -5.3% | -2.5% | -4.2% | -6.4% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $44.92 | $45.40 | +1.1% | -3.8% | -5.3% | -2.5% | -4.2% | -6.4% |
| Jan 9 | JP Morgan | Maintains | Overweight → Overweight | — | $41.22 | $41.55 | +0.8% | +2.3% | +0.0% | -2.1% | +0.9% | -1.2% |
| Dec 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $43.44 | $43.44 | +0.0% | +0.5% | +1.4% | +0.4% | -1.0% | -1.0% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $40.61 | $40.60 | -0.0% | +0.0% | +0.1% | -0.8% | +1.4% | +3.5% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $41.12 | $39.74 | -3.4% | -4.9% | -6.0% | -6.9% | -7.0% | -6.6% |
| Nov 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $41.12 | $39.74 | -3.4% | -4.9% | -6.0% | -6.9% | -7.0% | -6.6% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $41.12 | $39.74 | -3.4% | -4.9% | -6.0% | -6.9% | -7.0% | -6.6% |
| Oct 7 | Chardan Capital | Maintains | Buy → Buy | — | $39.55 | $39.16 | -1.0% | -1.0% | -0.8% | +4.4% | +0.2% | +1.1% |
| Sep 2 | RBC Capital | Maintains | Outperform → Outperform | — | $38.71 | $38.89 | +0.5% | +1.5% | +0.3% | -0.2% | +1.3% | -1.3% |
| Aug 12 | RBC Capital | Maintains | Outperform → Outperform | — | $34.11 | $36.00 | +5.5% | +5.5% | +10.4% | +11.3% | +12.1% | +10.9% |
| Aug 12 | Wedbush | Maintains | Outperform → Outperform | — | $34.11 | $36.00 | +5.5% | +5.5% | +10.4% | +11.3% | +12.1% | +10.9% |
| Aug 12 | Chardan Capital | Maintains | Buy → Buy | — | $34.11 | $36.00 | +5.5% | +5.5% | +10.4% | +11.3% | +12.1% | +10.9% |
| Jun 13 | RBC Capital | Maintains | Outperform → Outperform | — | $32.80 | $32.40 | -1.2% | -0.1% | -2.4% | -3.4% | -2.7% | -2.3% |
| May 13 | Needham | Maintains | Buy → Buy | — | $35.85 | $32.81 | -8.5% | -17.4% | -17.0% | -17.5% | -15.5% | -13.7% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $35.85 | $32.81 | -8.5% | -17.4% | -17.0% | -17.5% | -15.5% | -13.7% |
| May 13 | RBC Capital | Maintains | Outperform → Outperform | — | $35.85 | $32.81 | -8.5% | -17.4% | -17.0% | -17.5% | -15.5% | -13.7% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.85 | $32.81 | -8.5% | -17.4% | -17.0% | -17.5% | -15.5% | -13.7% |
| May 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $35.85 | $32.81 | -8.5% | -17.4% | -17.0% | -17.5% | -15.5% | -13.7% |
| Apr 17 | Goldman Sachs | Maintains | Buy → Buy | — | $33.78 | $33.71 | -0.2% | +3.9% | +2.7% | +8.7% | +11.3% | +13.1% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.73 | $39.59 | -0.4% | -3.4% | -5.2% | -1.6% | -3.6% | -6.8% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.97 | $42.62 | -0.8% | -8.2% | -6.8% | -3.9% | -3.9% | -8.4% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.39 | $43.08 | -0.7% | -3.3% | -3.8% | -8.2% | -11.7% | -10.5% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $43.39 | $43.08 | -0.7% | -3.3% | -3.8% | -8.2% | -11.7% | -10.5% |
| Sep 3 | RBC Capital | Maintains | Outperform → Outperform | — | $40.34 | $40.22 | -0.3% | -0.5% | +0.5% | -1.2% | -4.6% | -4.3% |
| Aug 12 | Needham | Maintains | Buy → Buy | — | $39.70 | $39.36 | -0.9% | -2.1% | -2.3% | -2.5% | -3.7% | -4.5% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $41.01 | $36.92 | -10.0% | -3.2% | -5.3% | -5.4% | -5.6% | -6.7% |
| Aug 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.01 | $36.92 | -10.0% | -3.2% | -5.3% | -5.4% | -5.6% | -6.7% |
| Jun 18 | RBC Capital | Maintains | Outperform → Outperform | — | $36.60 | $36.71 | +0.3% | -1.0% | +1.3% | +2.4% | +2.2% | +1.1% |
| May 10 | Citigroup | Maintains | Buy → Buy | — | $42.49 | $40.76 | -4.1% | -4.6% | -4.7% | -4.5% | -4.8% | -5.1% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $42.49 | $40.76 | -4.1% | -4.6% | -4.7% | -4.5% | -4.8% | -5.1% |
| May 10 | Needham | Maintains | Buy → Buy | — | $42.49 | $40.76 | -4.1% | -4.6% | -4.7% | -4.5% | -4.8% | -5.1% |
| Apr 12 | Needham | Maintains | Buy → Buy | — | $42.97 | $42.67 | -0.7% | -3.9% | -3.9% | -3.4% | -3.1% | -6.2% |
| Apr 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $43.03 | $42.58 | -1.0% | -1.4% | -0.1% | -4.0% | -4.0% | -3.6% |
| Mar 1 | RBC Capital | Maintains | Outperform → Outperform | — | $47.20 | $49.70 | +5.3% | -0.8% | -2.6% | -2.5% | -2.6% | -2.2% |
| Mar 1 | Needham | Maintains | Buy → Buy | — | $47.20 | $49.70 | +5.3% | -0.8% | -2.6% | -2.5% | -2.6% | -2.2% |
| Mar 1 | Wedbush | Maintains | Outperform → Outperform | — | $47.20 | $49.70 | +5.3% | -0.8% | -2.6% | -2.5% | -2.6% | -2.2% |
| Jan 2 | BofA Securities | Maintains | Buy → Buy | — | $46.06 | $45.49 | -1.2% | -2.5% | -4.1% | -0.1% | -1.2% | +4.0% |
| Dec 18 | Stifel | Maintains | Buy → Buy | — | $41.41 | $41.65 | +0.6% | -0.6% | +1.4% | -1.0% | +0.3% | +7.8% |
| Nov 28 | RBC Capital | Maintains | Outperform → Outperform | — | $34.12 | $34.42 | +0.9% | +3.3% | -1.1% | +7.2% | +7.9% | +10.7% |
| Nov 9 | Wedbush | Maintains | Outperform → Outperform | — | $32.15 | $33.42 | +4.0% | -6.7% | -10.3% | -7.6% | -7.5% | -9.3% |
| Sep 22 | RBC Capital | Maintains | Outperform → Outperform | — | $35.76 | $35.76 | +0.0% | -1.6% | -1.3% | -2.0% | -1.8% | -1.2% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $38.07 | $38.07 | +0.0% | +0.8% | +1.4% | +0.6% | -0.1% | +0.8% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Xenon Pharmaceuticals' leadership transition could signal strategic shifts in pipeline priorities or commercialization strategy, warranting investor attention to upcoming guidance and management commentary on R&D direction.
Apr 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis because the filing content appears corrupted or incomplete, containing only contact information and encoded graphics without substantive business disclosures needed to assess investment impact.
Mar 13
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
Xene Therapeutics raised $707.7 million in a securities offering, providing substantial capital for clinical development and operations, which reduces near-term dilution risk and strengthens the biotech's runway for advancing pipeline programs.
Mar 12
8-K · 7.01
! Medium
Xenon Pharmaceuticals Inc -- 8-K 7.01: Regulation FD Disclosure
Xenon Pharmaceuticals disclosed topline data results via investor presentation on March 9, 2026, signaling potential progress in clinical development that management intends to discuss with investors and analysts.
Mar 9
8-K · 8.01
!! High
Xenon Pharmaceuticals Inc -- 8-K 8.01: Material Event / Announcement
Xenon Pharmaceuticals terminated its prior offering after raising $291 million in share sales, replacing it with a new prospectus supplement for continued equity fundraising flexibility.
Feb 27
8-K · 7.01
! Medium
Xenon Pharmaceuticals Inc -- 8-K 7.01: Regulation FD Disclosure
Xenon Pharmaceuticals expanded its investor communication channels to include social media platforms X, LinkedIn, and Facebook, enabling broader real-time access to company updates and product development information.
Feb 26
Data updated apr 27, 2026 10:29am
· Source: massive.com